3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2018, it reported revenue of CNY 4.6 billion. Approximately 75% of its revenue is derived from three core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), and EPIAO (rhEPO), which are all older generation biologics. The company has a pipeline of 32 products, of which 22 are biologics and 10 are small molecules. Only two of these products are expected to launch within the next year: inetetamab (biosimilar of trastuzumab, a HER2 down-regulator) and Jiantuoxi (biosimilar of rituximab, an anti-CD20 antibody).
Shenyang, 110027, Cayman Islands